

1 **Safety of hyperbaric oxygen therapy in patients with heart**  
2 **failure: A retrospective review**

3

4 Simone Schiavo <sup>1,2</sup>, Connor T. A. Brenna <sup>1</sup>, Lisa Albertini <sup>3</sup>, George Djaiani <sup>1,2</sup>,

5 Anton Marinov <sup>1,4</sup>, Rita Katznelson <sup>1,2,4</sup>

6

7 <sup>1</sup> Department of Anesthesiology & Pain Medicine, University of Toronto, Toronto, ON, Canada

8 <sup>2</sup> Hyperbaric Medicine Unit, Toronto General Hospital, Toronto, ON, Canada;

9 [hyperbaricmedicineunit@uhn.ca](mailto:hyperbaricmedicineunit@uhn.ca) Department of Anesthesia and Pain Management, University Health Network,

10 Toronto, ON, Canada

11 <sup>3</sup> Department of Medicine, Division of Cardiology, University of Toronto, Toronto, ON, Canada

12 <sup>4</sup>Rouge Valley Hyperbaric Medical Center, Scarborough, ON, Canada

13

14 Corresponding author: Rita Katznelson, [rita.katznelson@uhn.ca](mailto:rita.katznelson@uhn.ca)

## 15 **Abstract**

16 **Background:** Hyperbaric oxygen therapy (HBOT) has several hemodynamic effects including  
17 increases in afterload (due to vasoconstriction) and decreases in cardiac output. This, along  
18 with rare reports of pulmonary edema during emergency treatment, has led providers to  
19 consider HBOT relatively contraindicated in patients with reduced left ventricular ejection  
20 fraction (LVEF). However, there is limited evidence regarding the safety of elective HBOT in  
21 patients with heart failure (HF), and no existing reports of complications among patients with  
22 HF and preserved LVEF. We aimed to retrospectively review patients with preexisting diagnoses  
23 of HF who underwent elective HBOT, to analyze HBOT-related acute HF complications.

24 **Methods:** Research Ethics Board approvals were received to retrospectively review patient  
25 charts. Patients with a history of HF with either preserved ejection fraction (HFpEF), mid-range  
26 ejection fraction (HFmEF), or reduced ejection fraction (HFrEF) who underwent elective HBOT  
27 at two Hyperbaric Centers (Toronto General Hospital, Rouge Valley Hyperbaric Medical Centre)  
28 between June 2018 and December 2020 were reviewed.

29 **Results:** Twenty-three patients with a history of HF underwent HBOT, completing an average of  
30 39 (range 6 – 62) consecutive sessions at 2.0 atmospheres absolute (ATA) (n=11) or at 2.4 ATA  
31 (n=12); only two patients received fewer than 10 sessions. Thirteen patients had HFpEF (mean  
32 LVEF  $55 \pm 7\%$ ), and seven patients had HFrEF (mean LVEF  $35 \pm 8\%$ ) as well as concomitantly  
33 decreased right ventricle function (n=5), moderate/severe tricuspid regurgitation (n=3), or  
34 pulmonary hypertension (n=5). The remaining three patients had HFmEF (mean LVEF  $44 \pm 4\%$ ).  
35 All but one patient was receiving fluid balance therapy either with loop diuretics or dialysis.

36 Twenty-one patients completed HBOT without complications. We observed symptoms  
37 consistent with HBOT-related HF exacerbation in two patients. One patient with HFrEF (LVEF  
38 24%) developed dyspnea attributed to pulmonary edema after the fourth treatment, and later  
39 admitted to voluntarily holding his diuretics before the session. He was managed with  
40 increased oral diuretics as an outpatient, and ultimately completed a course of 33 HBOT  
41 sessions uneventfully. Another patient with HFpEF (LVEF 64%) developed dyspnea and  
42 desaturation after six sessions, requiring hospital admission. Acute coronary ischemia and  
43 pulmonary embolism were ruled out, and an elevated BNP and normal LVEF on echocardiogram  
44 confirmed a diagnosis of pulmonary edema in the context of HFpEF. Symptoms subsided after  
45 diuretic treatment and the patient was discharged home in stable condition, but elected not to  
46 resume HBOT.

47 **Conclusions:** Patients with HF, including HFpEF, may develop HF symptoms during HBOT and  
48 warrant ongoing surveillance. However, these patients can receive HBOT safely after  
49 optimization of HF therapy and fluid restriction.

50

51 **Introduction**

52           Hyperbaric oxygen therapy (HBOT) is an evidence-based intervention used to treat a  
53 variety of elective conditions, in addition to its role as an emergency treatment for carbon  
54 monoxide toxicity, decompression sickness, and arterial gas embolism (S1 Table) (1). The safety  
55 profile of HBOT is very favorable: although minor side effects related to increased environmental  
56 pressure and/or systemic hyperoxia can occur (e.g., claustrophobia, transient myopia, or middle  
57 ear barotrauma) (2-4), serious treatment complications (e.g., seizures, pulmonary oxygen  
58 toxicity, or pulmonary edema) are extremely rare (5). Anecdotal evidence has suggested that  
59 patients with decreased left ventricular ejection fraction (LVEF) may be at an increased risk of  
60 acute heart failure (HF) during HBOT (6). Although this risk has not been substantiated by robust  
61 evidence, left ventricular (LV) systolic dysfunction has traditionally been considered a relative  
62 contraindication to HBOT (6).

63           Several hemodynamic changes are known to occur during and immediately after  
64 hyperbaric oxygen exposure (7). HBOT increases cardiovascular afterload, with associated  
65 increases in systolic and mean arterial blood pressure (BP), while cardiac output (CO) decreases  
66 due primarily to a decrease in heart rate (HR). Previous literature characterizing the effect of  
67 HBOT on CO is summarized in Table 1.

68

69 **Table 1. Previous studies characterizing the effect of hyperbaric oxygen therapy on cardiac**  
70 **output.**

Study	CO change	ATA
-------	-----------	-----

	(% compared to baseline)	
Whalen, 1965 (8)	-13	3.04
Pisarello, 1987 (9)	-8	3.0
	-15	2.5
Pelaia, 1992 (10)	-17	2.2
McMahon, 2002 (11)	-10	3.0
Weaver, 2009 (12)	-18	2.5
	-16	3.0

71 Changes in cardiac output associated with hyperbaric oxygen therapy among previous reports.

72 Abbreviations: CO = cardiac output, ATA = absolute atmospheres of pressure.

73 Numerous mechanisms for the effect of HBOT on CO have been suggested (13, 14)

74 although this effect predominately results from HBOT-induced vasoconstriction, the

75 physiological protective response to extremely high arterial partial pressures of oxygen (7). These

76 hemodynamic changes appear to be well tolerated in patients without preexisting cardiac disease

77 (15, 16). However, there is limited evidence regarding the applicability of HBOT in patients with

78 HF and reduced ejection fraction (HFrEF) and, furthermore, no data on patients with HF with

79 preserved ejection fraction (HFpEF) or HF with mid-range ejection fraction (HFmEF). We aimed

80 to examine the safety of HBOT for patients with preexisting diagnoses of HF.

81

82

## 83 **Methods**

### 84 **Study design**

85           This is a retrospective longitudinal cohort study of patients with HF who underwent  
86 elective HBOT between June 2018 and December 2020 in two Hyperbaric Medicine Centers in  
87 Ontario, Canada (Toronto General Hospital, Toronto; Rouge Valley Hyperbaric Medical Centre,  
88 Scarborough). Institutional Research Ethics Board approvals (CAPCR ID: 19-5081.1; IRB ID:2023-  
89 3194-14092-4) were obtained for study team members to collect data from medical records (last  
90 access to data on March 31, 2023; all authors but one (SS) did not have access to information  
91 that could identify individual participants during or after data collection).

92

### 93 **Definitions**

94           In accordance with the Canadian Cardiovascular society guidelines (17), HF was defined  
95 as a clinical syndrome in which abnormal heart function results in (or increases the risk of) clinical  
96 symptoms and signs of reduced cardiac output and/or pulmonary or systemic congestion either  
97 at rest or with stress. Chronic HF represents the persistent and progressive nature of the disease,  
98 whereas acute HF is defined as a change in HF signs and symptoms resulting in the need for  
99 urgent therapy. Recent guidelines proposed a new and revised classification of HF according to  
100 LVEF (18-20), which includes: (i) HF with preserved ejection fraction (HFpEF) = LVEF  $\geq$  50%; (ii) HF  
101 with mid-range ejection fraction (HFmEF) = LVEF 41-49%; and (iii) HF with reduced ejection  
102 fraction (HFrEF) = LVEF  $\leq$  40%.

103 HFpEF is diagnosed in patients with signs and symptoms of HF as the result of high LV  
104 filling pressure, despite preserved LVEF ( $\geq 50\%$ ) (18). These patients also display normal LV  
105 volumes and an abnormal diastolic filling pattern (diastolic dysfunction) (18, 21); therefore,  
106 HFpEF is sometimes referred to as diastolic heart failure (22, 23).

107

## 108 **Participants and data collection**

109 We included all patients 18 years of age or older with a history of HF, regardless of EF,  
110 undergoing elective HBOT during the study period. To further categorize these patients, LVEF  
111 measurements via echocardiography were identified (where available) and used to stratify  
112 patients into three groups: (i) HFpEF = LVEF  $\geq 50\%$ ; (ii) HFmEF = LVEF 41 – 49%; and (iii) HFrEF =  
113 LVEF  $\leq 40\%$  (17).

114 Each patient's demographic variables, past medical history, and medications were  
115 extracted from medical charts. Additional data extracted during the treatment period included  
116 HBOT indication, treatment pressure, total number of HBOT sessions, and adverse events  
117 associated with HBOT, including subjective symptoms reported by the patients and reported into  
118 the medical chart. All patients described in the study provided written consent to undergo HBOT  
119 for a clinical indication approved by Health Canada.

120

## 121 **Hyperbaric oxygen therapy protocol**

122 Conventional HBOT protocols were utilized in the treatment of all patients, as previously  
123 described (15): these included the administration of 100% oxygen at 2.0 or 2.4 atmospheres

124 absolute (ATA) for 90 minutes, with 1 – 2 air breaks (0.21 fraction of inspired O<sub>2</sub> at the same ATA)  
125 per session, five times weekly, either in a mono-place chambers (Sechrist 3600H and Sechrist  
126 4100H, Sechrist Industries Inc., Anaheim, CA, USA; PAH-S1-3200, Pan-America Hyperbarics Inc.,  
127 Plano, TX, USA; Sigma 36, Perry Baromedical, Riviera Beach, FL, USA) or through a plastic hood in  
128 the multi-place chamber (rectangular Hyperbaric System, Fink Engineering PTY-LTD, Warana,  
129 Australia). Standard monitoring included measurements of systolic (SAP), diastolic (DAP), and  
130 mean (MAP) blood pressure (BP), heart rate (HR), and peripheral oxygen saturation (SpO<sub>2</sub>)  
131 assessed during a five-minute period preceding and following each HBOT session. BP was  
132 measured non-invasively using an upper arm cuff and automated sphygmomanometer (Connex  
133 VSM 6000, WelchAllyn—Hill-Rom, New York, NY, USA) with the patient in a sitting or semi-sitting  
134 position.

135

## 136 **Outcomes**

137 The objective of this study was to evaluate the safety of HBOT among patients with known  
138 HF. The primary outcome was to describe any clinical signs or symptoms of acute heart failure  
139 occurring during and immediately after HBOT. Secondary outcomes included other treatment  
140 complications, assessed as the number of patients experiencing HBOT-related adverse or serious  
141 adverse events, such as barotrauma, oxygen toxicity (either central nervous system or  
142 pulmonary), ocular changes, or confinement anxiety.

143

## 144 **Statistical analysis**

145           Qualitative data including patient demographics and past medical history characteristics  
146 were summarized using descriptive statistics. Continuous data were expressed as means  $\pm$   
147 standard deviations.

148 **Results**

149 **Clinical data**

150 During the study period, 23 patients with a documented diagnosis of HF received elective  
 151 HBOT. Table 2 summarizes patients' details and HBOT characteristics.

152 **Table 2. Baseline demographics, comorbidities, and medications of the patient cohort.**

<b>n= 23</b>	
Age (years)	70 ± 12
Body Mass Index (kg/m <sup>2</sup> )	31 ± 11
Female	8
<b>Comorbidities</b>	
History of hypertension	21
Baseline Heart Failure classification:	13
<i>Preserved EF (LVEF ≥ 50%)</i>	3
<i>Mid-range EF (LVEF 41-49%)</i>	7
<i>Reduced EF (LVEF ≤ 40%)</i>	
Coronary artery disease	14
Left ventricular hypertrophy	7
Heart valvular disease	6
Diastolic dysfunction	7
Atrial fibrillation	9
Peripheral vascular disease	11
Diabetes mellitus:	
<i>Type 1</i>	2
<i>Type 2</i>	16
Chronic obstructive pulmonary disease	5
Restrictive lung disease	0
Smoking status:	
<i>Never</i>	15
<i>Current</i>	2
<i>Past</i>	6
Renal insufficiency	14
Dialysis	5
<b>Medications</b>	
ACEi/ARBs	11
B-blockers	15
Calcium channel blockers	13
Diuretics	18
Vasodilators	6
<b>HBOT Pressure (2.4 ATA)</b>	12

153 Descriptive analysis of patients included in this study (n = 23). Abbreviations: EF = ejection  
154 fraction, LVEF = left ventricular ejection fraction, ACEi = angiotensin-converting enzyme  
155 inhibitor, ARB = angiotensin receptor blocker, ATA = absolute atmospheres of pressure.

156  
157 The mean patient age was  $70 \pm 12$  years and 15 (65%) were male. A majority of patients  
158 had comorbid diagnoses of hypertension (21; 91%), type 2 diabetes (16; 70%), and/or coronary  
159 artery disease (14; 61%). At baseline, 13 (57%), 3 (13%), and 7 (30%) patients had HF categorized  
160 as HFpEF ( $\geq 50\%$ ), HFmEF (41 – 49%) and HFrEF ( $\leq 40\%$ ), respectively. All 10 patients with HFrEF  
161 or HFmEF (100%) had a prior hospitalization for HF, compared to 7 out of 13 (54%) of patients  
162 with HFpEF. Overall, 11 (48%) were receiving treatment with ACEi/ARBs, 15 (65%) with  
163 betablockers, and 18 (78%) with diuretics, including 16 with loop diuretics, one with thiazide  
164 diuretics and one with potassium-sparing diuretics. Five (22%) patients were on dialysis, including  
165 one concurrently receiving diuretics, and only one patient with HFpEF was not receiving any  
166 diuretic nor dialysis. Pre-HBOT, all but one patient underwent a transthoracic echocardiography  
167 (Table 2) in addition to a clinical assessment which excluded signs of acute heart failure prior to  
168 compression.

169

## 170 **HBOT characteristics**

171 Twelve patients received HBOT at a pressure of 2.4 ATA; the remaining 11 patients  
172 underwent treatment at 2.0 ATA. Collectively, the 23 patients described in this study completed  
173 a total of 906 HBOT sessions. Each patient underwent an average of  $39 \pm 17$  treatments, and half

174 of them (434; 48%) were delivered at 2.4 ATA. Table 3 summarizes details of treatment for each  
 175 patient.

176 **Table 3. Hyperbaric oxygen therapy details.**

Patient #	LVEF (%)	ATA prescribed	Total number of treatments	Indication
1	34	2.4	26	AI LL
2	54	2.4	60	DFU
3	66	2.4	35	AI LL
4	33	2.4	35	STRI-RC
5	55	2.4	23	ORN (jaw)
6	50	2.4	58	DFU
7	52	2.4	50	DFU
8	45	2.4	40	AI LL
9	31	2.0	49	DFU
10	50	2.4	60	CPHYX
11	24	2.4	33 *	CPHYX
12	64	2.4	6	DFU
13	40	2.4	8	CPHYX
14	52	2.0	50	DFU
15	56	2.0	60	DFU
16	48	2.0	42	DFU
17	32	2.0	30	DFU
18	51	2.0	62	DFU
19	30	2.0	17	DFU
20	50	2.0	36	DFU
21		2.0	60	STRI-RP
22	50	2.0	41	CPHYX
23	52	2.0	25	DFU

177 Treatment details for each patient included in the cohort (n = 23), including LVEF, HBOT  
178 exposure pressure, number of sessions, indications for HBOT, and treatment center.  
179 Abbreviations: HBOT = hyperbaric oxygen therapy; ATA = absolute atmospheres of pressure;  
180 LVEF = left ventricle ejection fraction; AI LL = arterial insufficiency – lower extremity; DFU =  
181 diabetic foot ulcer; STRI = soft tissue radiation injury; RC = radiation cystitis; RP = radiation  
182 proctitis; ORN = osteoradionecrosis; CPHYX = calciphylaxis. \*Patient #11: 7 out of the 33  
183 sessions were at 2.0 ATA, and the remainder at 2.4 ATA.

184  
185

## 186 **Acute cardiovascular complications**

187 We observed symptoms consistent with HBOT-related HF in two patients (2/23, 9%). One  
188 patient with HFrEF (LVEF 24%) developed dyspnea after their fourth treatment for a diabetic foot  
189 ulcer. He had a history of hypertension, non-ischemic dilated cardiomyopathy, left ventricle  
190 hypertrophy, moderate pulmonary hypertension, mild tricuspid regurgitation, moderate diastolic  
191 dysfunction, atrial fibrillation, peripheral vascular disease, obesity, diabetes, and kidney failure  
192 (not on dialysis). A routine random B-type Natriuretic peptide (BNP) collected one month before  
193 HBOT was 402 g/mL (Lab reference range: <= 99.9 pg/mL). Following HBOT, examination revealed  
194 an increased work of breathing and crackles consistent with pulmonary edema, without  
195 peripheral oxygen desaturation. In the emergency department, his BNP was measured at 1580  
196 pg/ml, and he was managed with increased oral diuretics but did not require hospitalization. This  
197 patient later disclosed that he had voluntarily held his diuretics before the treatment to avoid

198 needing to urinate while inside the hyperbaric chamber. He subsequently continued HBOT,  
199 completing a total of 33 sessions without further complication.

200 A second patient, with HFpEF (LVEF 74%), developed dyspnea and desaturation after the  
201 sixth treatment session (also for a diabetic foot ulcer), ultimately requiring hospital admission.  
202 He had a history of hypertension, type 2 diabetes on insulin, obesity, coronary artery disease with  
203 HFpEF, and mild diastolic dysfunction (on double diuretic therapy). His hypertension was  
204 reported as well controlled on dual therapy (nifedipine and telmisartan), but a review of his BP  
205 measured before and after each session revealed a consistently increased SAP (mean  $155 \pm 11$   
206 mmHg) and normal DAP ( $77 \pm 4$  mmHg) before each treatment, and both an increased SAP ( $170$   
207  $\pm 3$  mmHg) and DAP ( $86 \pm 10$  mmHg) following each treatment. During the acute episode  
208 following his sixth HBOT session, acute coronary ischemia and pulmonary embolism were  
209 clinically excluded. A diagnosis of pulmonary edema in the context of HFpEF was made on the  
210 basis of an elevated BNP (143 pg/mL), pulmonary congestion identified through bedside lung  
211 ultrasound and chest X-ray, and normal LVEF with the presence of diastolic dysfunction on  
212 transthoracic echocardiogram. The patient's symptoms subsided after administration of an  
213 intravenous loop diuretic (furosemide), and he was discharged home in stable condition.  
214 However, he elected not to resume HBOT. Three years later, he died of an unrelated oncologic  
215 pathology.

216 No acute cardiovascular complications were observed among the other 21 patients.

217

218 **Other complications**

219 A total of seven non-serious adverse events were recorded: five instances of middle-ear  
220 barotrauma, and two of confinement anxiety. In each case, appropriate coaching and treatment  
221 were provided, and all patients continued HBOT without further complication.

222

## 223 **Discussion**

224 In this study we investigated whether patients with a history of HF can safely receive  
225 HBOT. Two patients in our cohort (9%) experienced acute symptoms of heart failure in relation  
226 to HBOT. One had a history of HFrEF, which portends a theoretical risk with respect to HBOT. The  
227 other had a history of HFpEF, which has not been previously reported to increase cardiac risks of  
228 HBOT.

229

### 230 **Heart failure with reduced ejection fraction**

231 HBOT is known to negatively impact cardiac output (CO), even among healthy patients  
232 (24). The decreased CO, along with an increased afterload resulting from systemic vascular  
233 resistance, has been hypothesized to be the cause of pulmonary edema reported in patients with  
234 reduced EF (6). In our cohort, among seven patients with HFrEF, only one developed signs of  
235 acute heart failure following HBOT. This patient had a severely impaired LVEF below 30% and he  
236 was receiving treatment with loop diuretics, although for two days he had been withholding his  
237 morning doses. With appropriate coaching and therapy optimization (an increase in the dose of

238 his loop diuretic), he continued HBOT and was able to complete 29 additional sessions without  
239 further complication. Our experience with these seven patients indicates that HBOT may  
240 exacerbate pulmonary congestion in patients with reduced ejection fraction, but also supports  
241 the feasibility of cautious treatment with close monitoring in this population after optimization  
242 of diuretic therapy. Interestingly, more recent studies have analyzed the long-term effects of  
243 HBOT on myocardial function, and paradoxically support a possible positive effect of HBOT on  
244 LVEF and other echocardiographic measures over longer time horizons (25-27).

245

## 246 **Heart failure with preserved ejection fraction**

247 One of the 13 patients with HFpEF in our cohort developed acute signs of heart failure  
248 after six HBOT sessions. He had a history of hypertension, previous admission for heart failure,  
249 echocardiographic evidence of diastolic dysfunction, and ongoing treatment with thiazide  
250 diuretics but not loop diuretics. His consistently increased SAP and DAP post-sessions may  
251 suggest a marked increase in afterload during and after each session (15), and increased afterload  
252 is a well-known effect of HBOT which contributes to decreases in CO (6, 12). Further, there is  
253 evidence that hyperoxia increases LV end-diastolic pressure (LVEDP), and it is associated with  
254 disturbances of both early and late phases of LV filling in patients with and without HF (28). As a  
255 result, it is possible that a combination of increased afterload and impaired ventricular relaxation  
256 in the context of preexisting diastolic dysfunction might represent the mechanism of the  
257 pulmonary congestion exacerbation in this patient.

258           Complications of HFpEF resulting from HBOT have not been previously reported, although  
259 this finding is important as HFpEF is more prevalent among older adults, women, and those with  
260 obesity, systemic arterial hypertension, diabetes mellitus, and renal dysfunction (29). Given the  
261 aging population and the increased medical complexity of patients seen in modern hyperbaric  
262 centres, the authors expect an increasing frequency of HBOT candidates with HFpEF in the  
263 hyperbaric medicine setting.

264

## 265 **Clinical implications**

266           Our data suggest that a minority of patients with HF, regardless of EF, may develop acute  
267 heart failure symptoms. However, we also show that this event is rare and potentially  
268 preventable, and that these patients can complete HBOT safely after therapy optimization, with  
269 close surveillance before and after each session. Cardiac guidelines recommend the use of loop  
270 diuretics in patients with HFpEF and HFrEF, aiming to reduce symptoms of congestion (18, 20). In  
271 our study, no complications were observed among 21 patients out of 23. Interestingly, all but  
272 one of these patients were either on therapy with loop diuretics or receiving regular dialysis. It is  
273 possible that optimizing medical therapy (e.g., initiating or titrating loop diuretics) for patients  
274 with HFpEF may avoid or further limit pulmonary congestion in the setting of HBOT.

275           Some HF patients may present for HBOT without the typical history of HF symptoms and  
276 low LVEF, well known to physicians as pathognomonic of HFrEF. Indeed, HFpEF is diagnostically  
277 challenging for a clinician, given the frequency of atypical symptoms and/or an unremarkable  
278 LVEF. In our study, 54% of patients with HFpEF did not have a prior hospitalization primarily

279 caused by their HF, and the diagnosis was based on transthoracic echocardiogram and signs  
280 and/or symptoms of HF while undergoing investigations for other indications (e.g., acute  
281 coronary syndrome, or additional tests required during dialysis or diabetes management).

282 Therefore, even in the absence of a known impairment in LVEF, particular attention to  
283 any changes in the patient's clinical condition and pharmacological management during HBOT is  
284 warranted, and even mild-to-moderate respiratory or cardiac symptoms during HBOT should  
285 trigger further investigation to rule out an acute or subacute episode of HF. Patients with multiple  
286 comorbidities treated with numerous medications should be aware that any changes in their  
287 medications during HBOT should be discussed with their hyperbaric physician.

288 For the same reason, the availability of a baseline echocardiogram to facilitate evaluation  
289 of diastolic dysfunction during the initial assessment, rather than relying on other tests  
290 traditionally performed prior to HBOT (e.g., electrocardiogram or chest x-ray), may further  
291 reduce the risk of patients with unrecognized HF developing symptoms in the context of HBOT.  
292 However, there is currently a paucity of evidence to define the feasibility or cost-effectiveness of  
293 routine cardiac screening before HBOT to prevent these complications.

294 Finally, both patients who experienced HBOT-related HF in our study developed  
295 symptoms after several treatment sessions, rather than after the first one, suggesting the  
296 possibility of a cumulative effect of HBOT on pulmonary congestion (rather than acute onset,  
297 severe pulmonary edema in a patient who is incidentally referred for HBOT on the brink of this  
298 complication). This observation warrants particular consideration in the care of HF patients  
299 undergoing HBOT: despite undergoing several uneventful treatment sessions, these patients may

300 gradually worsen, and still require close surveillance for the entire duration of treatment. Further  
301 research is needed to characterize the optimal management of patients with HF undergoing  
302 HBOT.

303

## 304 **Limitations**

305         Our retrospective study has several inherent limitations. Because we retrospectively  
306 reviewed health records already compiled at the time of HBOT, it is possible that not all pertinent  
307 risk factors were identified and recorded. Our data relate to a cohort of patients treated in two  
308 urban centres, potentially limiting their generalizability to other settings; similarly, patients were  
309 treated by several different healthcare professionals at these settings, limiting consistency in  
310 measurement and reporting. Importantly, our study design cannot appreciate patients with HF  
311 who may have been referred for HBOT, assessed, and considered to be at too great a risk to  
312 proceed with treatment. Additionally, due to the rarity of patients with HF undergoing HBOT, we  
313 report on a small sample size, limiting estimates of the incidence of HF exacerbation related to  
314 HBOT, and subgroup analyses (e.g., stratified by EF %) present data on even smaller groups of  
315 patients. Finally, the primary outcome of the study was observational, and while two patients  
316 experienced symptoms of acute HF following HBOT with a close temporal relationship this cannot  
317 prove a causative relationship, especially considering the presence of possible confounding  
318 variables (e.g., types of and adherence to diuretics, changes in treatment pressure, and  
319 positioning after the complication).

320

## 321 **Conclusion**

322           Patients with a history of heart failure, whether HFpEF or HFrEF, may develop symptoms  
323 of pulmonary congestion during or after HBOT. However, they can safely complete HBOT  
324 following medical optimization with close attention paid to any clinical or pharmacological  
325 changes during treatment. Identifying patients at risk of HF exacerbation, and taking these  
326 measures to prevent acute symptoms during treatment, is an important objective of the pre-  
327 HBOT medical assessment.

328

## 329 **References**

- 330 1. Moon R UHMS. Hyperbaric Oxygen Therapy Indications. 14th, ed2019.
- 331 2. Jain KK. Indications, Contraindications, and Complications of HBO Therapy. In: Jain KK, editor.  
332 Textbook of Hyperbaric Medicine: Springer; 2017. p. 79-84.
- 333 3. Shupak A, Gilbey P. Effects of Pressure. Physiology and Medicine of Hyperbaric Oxygen  
334 Therapy2008. p. 513-26.
- 335 4. Heyboer M, 3rd, Wojcik SM, Grant WD, Chambers P, Jennings S, Adcock P. Middle ear  
336 barotrauma in hyperbaric oxygen therapy. Undersea Hyperb Med. 2014;41(5):393-7.
- 337 5. Heyboer M, 3rd, Sharma D, Santiago W, McCulloch N. Hyperbaric Oxygen Therapy: Side Effects  
338 Defined and Quantified. Adv Wound Care (New Rochelle). 2017;6(6):210-24.
- 339 6. Weaver LK, Churchill S. Pulmonary edema associated with hyperbaric oxygen therapy. Chest.  
340 2001;120(4):1407-9.
- 341 7. Mathieu D, Favory R, Collet F, Linke J-C, Wattel F. Physiologic Effects of Hyperbaric Oxygen on  
342 Hemodynamics and Microcirculation. Handbook on Hyperbaric Medicine: Springer-Verlag; 2006. p. 75-  
343 101.
- 344 8. Whalen RE, Saltzman HA, Holloway DH, Jr., McIntosh HD, Sieker HO, Brown IW, Jr.  
345 Cardiovascular and Blood Gas Responses to Hyperbaric Oxygenation. Am J Cardiol. 1965;15(5):638-46.
- 346 9. Pisarello JB CJ, Lambertsen CJ, Gelfand R, editor Human circulatory responses to prolonged  
347 hyperbaric hyperoxia in Predictive Studies V. Proceedings of the Ninth International Symposium on  
348 Underwater and Hyperbaric Physiology, Undersea and Hyperbaric Medical Society; 1987.
- 349 10. Pelaia P RM, Conti G, De Blasi RA, Bufi M, Antonelli M, Bortone C. Hemodynamic modifications  
350 during hyperbaric oxygen therapy. J Hyperb Med. 1992;7(4):229-37.

- 351 11. McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, et al. Nitric oxide in  
352 the human respiratory cycle. *Nat Med.* 2002;8(7):711-7.
- 353 12. Weaver LK, Howe S, Snow GL, Deru K. Arterial and pulmonary arterial hemodynamics and  
354 oxygen delivery/extraction in normal humans exposed to hyperbaric air and oxygen. *J Appl Physiol*  
355 (1985). 2009;107(1):336-45.
- 356 13. Nakada T, Koike H, Katayama T, Watanabe H, Yamori Y. Increased adrenal epinephrine and  
357 norepinephrine in spontaneously hypertensive rats treated with hyperbaric oxygen. *Hinyokika kiyo Acta*  
358 *urologica Japonica.* 1984;30(10):1357-66.
- 359 14. Heyboer Rd M, Wojcik SM, Smith G, Santiago W. Effect of hyperbaric oxygen therapy on blood  
360 pressure in patients undergoing treatment. *Undersea Hyperb Med.* 2017;44(2):93-9.
- 361 15. Schiavo S, Djaiani C, DeBacker J, Albertini L, Santa Mina D, Buryk-Iggers S, et al. Magnitude and  
362 Clinical Predictors of Blood Pressure Changes in Patients Undergoing Hyperbaric Oxygen Therapy: A  
363 Retrospective Study. *Int J Environ Res Public Health.* 2020;17(20).
- 364 16. Molenat F, Boussuges A, Grandfond A, Rostain JC, Sainty JM, Robinet C, et al. Haemodynamic  
365 effects of hyperbaric hyperoxia in healthy volunteers: an echocardiographic and Doppler study. *Clin Sci*  
366 (Lond). 2004;106(4):389-95.
- 367 17. Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017  
368 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart  
369 Failure. *Can J Cardiol.* 2017;33(11):1342-433.
- 370 18. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC  
371 Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.*  
372 2021;42(36):3599-726.
- 373 19. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal  
374 definition and classification of heart failure: a report of the Heart Failure Society of America, Heart

375 Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing  
376 Committee of the Universal Definition of Heart Failure. *European Journal of Heart Failure*.  
377 2021;23(3):352-80.

378 20. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA  
379 Guideline for the Management of Heart Failure: A Report of the American College of  
380 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*.  
381 2022;145(18):e895-e1032.

382 21. Gazewood JD, Turner PL. Heart Failure with Preserved Ejection Fraction: Diagnosis and  
383 Management. *Am Fam Physician*. 2017;96(9):582-8.

384 22. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology,  
385 diagnosis, and treatment. *Eur Heart J*. 2011;32(6):670-9.

386 23. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. *N Engl J Med*.  
387 2004;351(11):1097-105.

388 24. Kenmure AC, Murdoch WR, Hutton I, Cameron AJ. Hemodynamic effects of oxygen at 1 and 2  
389 Ata pressure in healthy subjects. *J Appl Physiol*. 1972;32(2):223-6.

390 25. Leitman M, Efrati S, Fuchs S, Hadanny A, Vered Z. The effect of hyperbaric oxygenation therapy  
391 on myocardial function. *Int J Cardiovasc Imaging*. 2020;36(5):833-40.

392 26. Li Y, Hao Y, Wang T, Wei L, Wang W, Liang Y, et al. The Effect of Hyperbaric Oxygen Therapy on  
393 Myocardial Perfusion after the Implantation of Drug-Eluting Stents. *Ann Clin Lab Sci*. 2018;48(2):158-63.

394 27. Aparci M, Kardesoglu E, Suleymanoglu S, Uzun G, Onem Y, Uz O, et al. Hyperbaric oxygen  
395 therapy improves myocardial diastolic function in diabetic patients. *Tohoku J Exp Med*. 2008;214(3):281-  
396 9.

397 28. Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular function and filling  
398 pressures in patients with and without congestive heart failure. *Chest*. 2001;120(2):467-73.

399 29. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart  
400 failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus  
401 recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).  
402 Eur J Heart Fail. 2020;22(3):391-412.

403

404

405 **Supporting information**

406 **S1 Table. Approved Indications for Hyperbaric Oxygen Therapy in Canada and the United**

407 **States.** Hyperbaric oxygen therapy indications approved by Health Canada (\*) or the US Food

408 and Drug Administration (†). Unlabeled items are approved by both agencies.